Optogenetic Therapy for Restoring Aspects of Visual Function.

Optogenetic therapy targeting retinal ganglion cells increased light sensitivity in 70% of advanced retinitis pigmentosa patients, with 60% showing clinically meaningful improvements.

• Why it matters: Retinitis pigmentosa causes irreversible blindness, and current treatments are limited, highlighting the need for innovative approaches to restore visual function in late-stage disease.
• What they did: The study involved 10 participants receiving a single intravitreal injection of an AAV vector encoding ChrimsonR, combined with light-stimulating goggles, to evaluate safety and changes in light sensitivity.
• The result: While adverse events were common, mostly mild, the therapy was deemed safe, and significant increases in light sensitivity suggest potential for restoring aspects of vision, warranting further research.